September 17, 2014
ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for small cell lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at the Orphan Drugs Summit to be held in Copenhagen, Denmark from September 17-19, 2014. Conference agenda information are available at www.orphandrugssummit.com. Mr. Adams will highlight recent results of Tozaride which demonstrated efficacy in an animal model of pancreatic cancer.
About Tozaride
Tozaride is a novel, best-in-class therapy for lung and other cancers based on a proprietary radio-labeled somatostatin peptide. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in heavily pre-treated advanced lung cancer patients. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) patients, and which will provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.
About Andarix
Andarix Pharmaceuticals is a clinical stage company developing targeted imaging agents and therapies for lung, neuroendocrine, and other cancers based on a proprietary somatostatin peptide conjugate. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung cancers. Lung cancer is the leading cause of cancer mortality in the United States for both men and women. To learn more about Andarix, please visit www.andarix.com
Contact:
Andarix Pharmaceuticals
617-957-9858
info@andarix.com